ACURA PHARMACEUTICALS, INC 4/A
4/A · ACURA PHARMACEUTICALS, INC · Filed Jan 26, 2015
Insider Transaction Report
Form 4/AAmended
CLAUDIUS LLC
10% Owner
Transactions
- Sale
Common Stock
2015-01-08$0.60/sh−100,000$60,180→ 11,154,497 total(indirect: See FN) - Sale
Common Stock
2015-01-12$0.64/sh−35,000$22,456→ 11,083,497 total(indirect: See FN) - Sale
Common Stock
2015-01-09$0.65/sh−36,000$23,436→ 11,118,497 total(indirect: See FN)
Footnotes (9)
- [F1]The shares were sold as follows: 91,356 by Galen Partners III, L.P. ("Galen III"), 8,268 by Galen Partners International III, L.P. ("Galen International") and 376 by Galen Employee Fund III, L.P. ("Employee Fund").
- [F2]The shares were sold at prices between $0.59 and $0.621. The Reporting Entities will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]The shares are held as follows: 10,193,315 by Galen III, 919,192 by Galen International and 41,990 by Employee Fund. Claudius, L.L.C. serves as the sole General Partner of Galen III and Galen International and has sole voting and investment control over the shares held by such funds and may be deemed to beneficially own the shares held by such funds. Galen Management, L.L.C. serves as the sole General Partner of Employee Fund and has sole voting and investment control over the shares held by Employee Fund and may be deemed to beneficially own the shares held by Employee Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein, except to the extent of its respective pecuniary interest therein.
- [F4]The shares were sold as follows: 32,888 by Galen III, 2,977 by Galen International and 135 by Employee Fund.
- [F5]The shares were sold at prices between $0.64 and $0.66. The Reporting Entities will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F6]The shares are held as follows: 10,160,427 by Galen III, 916,215 by Galen International and 41,855 by Employee Fund. Claudius, L.L.C. serves as the sole General Partner of Galen III and Galen International and has sole voting and investment control over the shares held by such funds and may be deemed to beneficially own the shares held by such funds. Galen Management, L.L.C. serves as the sole General Partner of Employee Fund and has sole voting and investment control over the shares held by Employee Fund and may be deemed to beneficially own the shares held by Employee Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein, except to the extent of its respective pecuniary interest therein.
- [F7]The shares were sold as follows: 31,974 by Galen III, 2,894 by Galen International and 132 by Employee Fund.
- [F8]The shares were sold at prices between $0.62 and $0.67. The Reporting Entities will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F9]The shares are held as follows: 10,128,453 by Galen III, 913,321 by Galen International and 41,723 by Employee Fund. Claudius, L.L.C. serves as the sole General Partner of Galen III and Galen International and has sole voting and investment control over the shares held by such funds and may be deemed to beneficially own the shares held by such funds. Galen Management, L.L.C. serves as the sole General Partner of Employee Fund and has sole voting and investment control over the shares held by Employee Fund and may be deemed to beneficially own the shares held by Employee Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein, except to the extent of its respective pecuniary interest therein.